BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: iTeos Therapeutics, Inc. (Nasdaq - ITOS), ZimVie Inc. (Nasdaq - ZIMV), PharmChem, Inc. (OTC - PCHM), NV5 Global, Inc. (Nasdaq - NVEE)

BALA CYNWYD, Pa., July 30, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

iTeos Therapeutics, Inc. (Nasdaq - ITOS)

Under the terms of the Merger Agreement, iTeos Therapeutics will be acquired by Concentra Biosciences, LLC (“Concentra”) for $10.047 in cash for each share of iTeos Therapeutics plus one non-transferable contingent value right (“CVR”), which represents the right to receive: (i) 100% of the closing net cash of iTeos in excess of $475 million; and (ii) 80% of any net proceeds received from any disposition of certain of iTeos’ product candidates that occurs within six months following the closing. The investigation concerns whether the iTeos Therapeutics Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company’s shareholders.

Additional information can be found at https://www.brodskysmith.com/cases/iteos-therapeutics-inc-nasdaq-itos/.

ZimVie Inc. (Nasdaq - ZIMV)

Under the terms of the agreement, ZimVie will be acquired by an affiliate of ARCHIMED (“ARCHIMED”) for $19.00 in cash for each share of ZimVie common stock outstanding at the closing of the transaction, corresponding to an enterprise value of approximately $730 million. The investigation concerns whether the ZimVie Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company’s shareholders.

Additional information can be found at https://www.brodskysmith.com/cases/zimvie-inc-nasdaq-zimv/.

PharmChem, Inc. (OTC - PCHM)

Under the terms of the Merger Agreement, PharmChem will be acquired by Alcohol Monitoring Systems, Inc. for $3.75 in cash for each share of PharmChem common stock outstanding at the closing of the transaction. The investigation concerns whether the PharmChem Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company’s shareholders.

Additional information can be found at https://www.brodskysmith.com/cases/pharmchem-inc-otc-pchm/.

NV5 Global, Inc. (Nasdaq - NVEE)

Under the terms of the agreement, NV5 Global will be acquired by Acuren Corporation (NYSE American - TIC) for $23.00 per share consisting of $10.00 in cash and $13.00 in shares of Acuren common stock at closing, subject to adjustment. The investigation concerns whether the NV5 Global Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company’s shareholders.

Additional information can be found at https://www.brodskysmith.com/cases/nv5-global-inc-nasdaq-nvee/.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.